• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024
 

World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024

on

  • 261 views

With Increasing Retinal Disease Prevalence and Unmet Clinical Needs ' Which Drug will be the Next Lucentis' The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy ...

With Increasing Retinal Disease Prevalence and Unmet Clinical Needs ' Which Drug will be the Next Lucentis' The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment of wet AMD. Our latest pharma report - World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 - examines prospects for the retinal disorder market over the next 15 years.The rapid commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful novel treatments in the retinal disorders market. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a condition for which there are currently no approved pharmacological treatments. Our analysts believe there are further commercial opportunities for new treatments for geographic atrophy (advanced dry AMD) and for wet AMD. There is a need for clear advantages over existing wet AMD therapies, for improved clinical outcomes and ease of dosing. This report analyses prospects there.Comprehensive analysis of the market areaWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures and three full interviews with experts in the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.Why you should buy World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024You will receive the following benefits when you order our report:' You will receive sales forecasts for the global retinal disorder market, AMD market,diabetic retinopathy market and the market for other retinal disorders, together with sales forecasts for leading brands, from 2009 to 2024' You will read expert opinion from key-opinion leaders in the retinal disorders pharmaceutical sector, including full transcripts of interviews not published elsewhere' You will gain a comprehensive assessment of strengths, weakness, opportunities and threats for this sector, including discussion of market drivers and restraints' You will receive an examination of the future prospects for Lucentis in the face of competition from off-label use of Avastin, with supporting market forecasts' You will obtain a regional analysis of the AMD and diabetic retinopathy markets, with sales forecasts' You will receive in-depth analyses of the pharmaceutical pipelines for AMD, diabetic retinopathy and other retinal disorders.You can obtain this report todayWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 will provide you with the information that you need to understand this dynamic and rapidly-expanding sector. Which pipeline drug candidates are the ones to watch' When are they likely to reach the market' In which geographical regions are AMD and diabetic retinopathy complications forecasted to increase most in prevalence' This new report answers those questions and much more besides. Do you want to know more about this

Statistics

Views

Total Views
261
Views on SlideShare
261
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Document Transcript

    • Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!World AMD and Diabetic Retinopathy Pharmaceutical Market2009-2024Published on July 2009 Report SummaryWith Increasing Retinal Disease Prevalence and Unmet Clinical Needs Which Drug will be the Next LucentisThe global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers ofolder people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetesand diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and otherretinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment ofwet AMD. Our latest pharma report - World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 - examines prospectsfor the retinal disorder market over the next 15 years.The rapid commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful novel treatments in theretinal disorders market. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a condition for which thereare currently no approved pharmacological treatments. Our analysts believe there are further commercial opportunities for newtreatments for geographic atrophy (advanced dry AMD) and for wet AMD. There is a need for clear advantages over existing wetAMD therapies, for improved clinical outcomes and ease of dosing. This report analyses prospects there.Comprehensive analysis of the market areaWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensivereview of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipelinedevelopments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figuresand three full interviews with experts in the sector. The result is a comprehensive market- and industry-centred report, with detailedanalyses and informed opinion to benefit your work.Why you should buy World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024You will receive the following benefits when you order our report: You will receive sales forecasts for the global retinal disorder market, AMD market,diabetic retinopathy market and the market forother retinal disorders, together with sales forecasts for leading brands, from 2009 to 2024 You will read expert opinion from key-opinion leaders in the retinal disorders pharmaceutical sector, including full transcripts ofinterviews not published elsewhere You will gain a comprehensive assessment of strengths, weakness, opportunities and threats for this sector, including discussion ofmarket drivers and restraints You will receive an examination of the future prospects for Lucentis in the face of competition from off-label use of Avastin, withsupporting market forecasts You will obtain a regional analysis of the AMD and diabetic retinopathy markets, with sales forecasts You will receive in-depth analyses of the pharmaceutical pipelines for AMD, diabetic retinopathy and other retinal disorders.You can obtain this report todayWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 1/10
    • Find Industry reports, Company profilesReportLinker and Market StatisticsWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 will provide you with the information that you need tounderstand this dynamic and rapidly-expanding sector. Which pipeline drug candidates are the ones to watch When are they likely toreach the market In which geographical regions are AMD and diabetic retinopathy complications forecasted to increase most inprevalence This new report answers those questions and much more besides. Do you want to know more about this Table of ContentTables of Content1 Executive Summary2 AMD and Diabetic Retinopathy2.1 The Eye2.1.1 The Human Eye2.1.2 The Retina and Vision2.2 Age-Related Macular Degeneration (AMD)2.2.1 Early Stages of AMD2.2.2 Advanced Dry AMD (Geographic Atrophy)2.2.3 Wet AMD2.2.4 AMD Causes and Risk Factors2.3 Diabetic Retinopathy (DR)2.3.1 Causes and Types of Diabetic Retinopathy2.3.2 Non-Proliferative Diabetic Retinopathy2.3.3 Diabetic Macular Edema2.3.4 Proliferative Diabetic Retinopathy (PDR)2.3.5 Risk Factors and Prevalence of Diabetic Retinopathy2.4 Diagnosis and Prevalence of AMD and DR2.4.1 Diagnosis2.4.2 Prevalence2.5 Other Retinal Disorders3 Treatments for AMD and Diabetic Retinopathy3.1 Treatment of Wet AMD3.1.1 Visudyne3.1.2 Macugen3.1.3 Retaane3.1.4 Lucentis3.1.5 Avastin3.2 Treatment of Dry AMD3.3 Treatments for Diabetic Retinopathy3.3.1 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy3.3.2 Triamcinolone Acetonide3.3.3 Lisinopril3.3.4 VEGF Inhibitors3.3.5 Dobesilate4 The World AMD and Diabetic Retinopathy Market, 2009-20244.1 The Retinal Disorder MarketWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 2/10
    • Find Industry reports, Company profilesReportLinker and Market Statistics4.1.1 The Retinal Disorder Market in 20084.1.2 Retinal Disorders Market Forecast, 2009-20144.1.3 Retinal Disorders Market Forecast, 2014-20244.2 The World AMD Market, 20084.2.1 Leading AMD Drugs in 20084.2.2 Leading AMD Drug Manufacturers4.3 AMD Market Forecast4.3.1 New Treatments for Geographic Atrophy: AMD Market Forecast, 2009-20144.3.2 AMD Market Forecast, 2014-20244.4 Diabetic Retinopathy Market4.4.1 The Diabetic Retinopathy Market in 20084.4.2 An Alternative to Surgery: Diabetic Retinopathy Market Forecast, 2009-20144.4.3 Diabetic Retinopathy Market Forecast, 2014-20244.5 Lucentis Sales Forecasts4.5.1 The Future of Lucentis Hinges on Off-Label Avastin Use4.5.2 Lucentis Sales Forecast, 2009-20144.5.3 Lucentis Sales Forecast, 2014-20244.5.4 Alternative Lucentis Sales Forecast, 2009-20244.6 Visudyne Sales Forecast, 2009-20145 The AMD and Diabetic Retinopathy Pipelines5.1 The Wet AMD Pipeline5.1.1 Monoclonal Antibodies and Corticosteroid Implants5.1.2 siRNA Molecules5.1.3 Stem Cells and Other Therapies5.2 The Dry AMD Pipeline5.3 The Diabetic Retinopathy Pipeline5.3.1 Corticosteroid Implants5.3.2 Anti-VEGF Treatments5.3.3 Early-Stage Diabetic Retinopathy Pipeline5.4 The Pipeline for Other Retinal Disorders5.5 AMD and DR Pipeline Drugs in Detail5.5.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)5.5.2 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)5.5.3 Bevasiranib (Opko)5.5.4 Avastin and Lucentis Comparison Trials (CATT)5.5.5 PF-4523655 (Quark/Pfizer)5.5.6 Visudyne and Lucentis (QLT/Novartis)5.5.7 Pazopanib (GSK)5.5.8 TG100801 (TargeGen)5.5.9 Zybrestat (Oxigene/Symphony ViDA)5.5.10 ATG-3 (CoMentis)5.5.11 Sirolimus (MacuSight/Santen)5.5.12 Iluvien (Alimera/pSivida)5.5.13 NT-501 (Neurotech)5.5.14 OT-551 (Othera)5.5.15 Sustained-Release Brimonidine (Allergan)5.5.16 Fenretinide (Sirion Therapeutics)5.5.17 NT-503 (Neurotech)5.5.18 Stem Cells (University College of London/Pfizer)World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 3/10
    • Find Industry reports, Company profilesReportLinker and Market Statistics5.5.19 Opkos siRNA Drug Candidates5.5.20 Arxxant (Eli Lilly/Alcon/Takeda)5.5.21 Lucentis (Roche/Novartis)5.5.22 Macugen (Pfizer)5.5.23 Vitreosolve (Vitreoretinal Technologies)5.5.24 Atacand/TCV-116 (AstraZeneca)5.5.25 Microplasmin (ThromboGenics)5.5.26 RPE65 Gene Therapy (Targeted Genetics)5.5.27 QLT091001 (QLT/Retinagenix)6 Issues Affecting the AMD and Diabetic Retinopathy Pharmaceutical Markets6.1 SWOT Analysis of the AMD and Diabetic Retinopathy Pharmaceutical Markets6.2 Intense Research and Development Activity6.2.1 New Drug Formulations6.2.2 Sustained-Release Ocular Implants6.2.3 Novel Biologic Drugs6.2.4 New Ophthalmic Therapeutic Applications for Drugs6.3 Off-Label Avastin Use for Retinal Disorders6.3.1 Avastin and Lucentis6.3.2 Off-Label Retinal Applications of Avastin6.3.3 History of Avastin Use for Wet AMD6.3.4 The CATT Study6.3.5 The Future for Off-Label Avastin6.4 Greying of the World Population6.5 Prevalence of Retinal Diseases6.5.1 Prevalence of AMD, 20086.5.2 Forecast AMD Prevalence, 20246.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 20086.5.4 Forecast Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 20246.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals6.6.1 Pressure on Healthcare in Current Difficult Economic Environment6.6.2 Prospects for Reimbursement for AMD and DR Drugs6.7 Diagnosis and Screening for Retinal Disorders6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs6.8.1 Current Laser Treatments6.8.2 Will Drugs Replace Laser Therapy7 AMD and Diabetic Retinopathy Regional Markets7.1 Retinal Disorder Country Markets, 20087.2 Retinal Disorder Regional Forecast, 2009-20247.2.1 The US Retinal Disorder Market, 2009-20247.2.2 The European Retinal Disorder Market, 2009-20247.2.3 The Retinal Disorder Market in the Rest of the World, 2009-20248 Opinion from Industry Experts8.1 Edward Danse, President and CEO of Neurotech8.1.1 Retinal Disorders with Greatest Unmet Patient Need8.1.2 Neurotechs AMD Pipeline8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients8.1.4 Screening Programmes for AMDWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 4/10
    • Find Industry reports, Company profilesReportLinker and Market Statistics8.1.5 Potential Lifetime of NT-501 in the Eye8.1.6 Other Potential Treatments for Geographic Atrophy8.1.7 Potential Use of NT-501 in Diabetic Retinopathy8.2 Ken Green, Ph.D., Chief Scientific Officer and Dave Holland, Founder/VP Marketing, Alimera Sciences8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients8.2.2 Development of Iluvien for Diabetic Macular Edema8.2.3 Update on Progress of Iluviens Phase III Trials8.2.4 Reimbursement Prospects for Corticosteroid Inserts8.2.5 Future for Laser Therapy in Diabetic Retinopathy8.2.6 Possible Future Treatment for Dry AMD and Geographic Atrophy8.2.7 Clinical Trials for Iluvien for Wet AMD and RVO8.3 Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals8.3.1 Otheras Geographic Atrophy Drug: OT-5518.3.2 New Drugs for Retinal Disorders Currently with No Treatments9 Conclusions9.1 AMD and Diabetic Retinopathy9.2 Increasing Prevalence of AMD and Diabetic Retinopathy9.3 Current Treatments for AMD and Diabetic Retinopathy9.4 The Retinal Disorder Market in 20089.5 Retinal Disorders Market Forecast, 2009-20249.6 Lucentis Market Forecast, 2009-20249.7 The AMD and Diabetic Retinopathy Pipelines9.8 The AMD Pipeline9.9 The Diabetic Retinopathy PipelineList of TablesTable 2.1 Wet AMD TypesTable 2.2 AMD and DR Diagnosis MethodsTable 2.3 Prevalence of AMD and DR, 2008Table 2.4 Other Retinal DisordersTable 3.1 Currently-Marketed AMD TreatmentsTable 3.2 Lucentis Regulatory Approval and Launch DatesTable 4.1 Retinal Disorder Market in 2008Table 4.2 World Retinal Disorders Market Forecast, 2009-2014Table 4.3 World Retinal Disorders Market Forecast, 2015-2024Table 4.4 AMD Market, 2008: Leading DrugsTable 4.5 AMD Market, 2008: Leading ManufacturersTable 4.6 Drivers and Restraints for the AMD Market, 2009-2014Table 4.7 Drivers and Restraints for the DR Market, 2009-2014Table 4.8 Drivers and Restraints for Lucentis Revenues, 2009-2014Table 4.9 Lucentis Market Forecast (Main Forecast), 2009-2014Table 4.10 Lucentis Market Forecast (Main Forecast), 2015-2024Table 4.11 Lucentis Market Forecast (Alternative Forecast), 2009-2014Table 4.12 Lucentis Market Forecast (Alternative Forecast), 2015-2024Table 4.13 Visudyne Market Forecast, 2009-2014Table 5.1 Key Late-Stage AMD Pipeline DrugsTable 5.2 Selected Early-Stage AMD Pipeline DrugsTable 5.3 Key Late-Stage Diabetic Retinopathy Pipeline DrugsWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 5/10
    • Find Industry reports, Company profilesReportLinker and Market StatisticsTable 5.4 Selected Early-Stage DR Pipeline DrugsTable 5.5 Other Retinal Disorder Pipeline DrugsTable 5.6 Lucentis Clinical Trials in ProgressTable 6.1 SWOT Chart for the AMD and DR Pharmaceutical Markets, 2009Table 6.2 World Population Forecast, 2008-2024Table 6.3 Population Forecasts in AMD and DR Markets, 2008 & 2024Table 6.4 Global, US and European AMD Prevalence, 2008Table 6.5 Forecast Global, US and European AMD Prevalence, 2024Table 6.6 Global, US and European DME, PDR and Diabetes Prevalence, 2008Table 6.7 Forecasted Global, US and European DME, PDR and Diabetes Prevalence, 2024Table 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008Table 7.2 Regional Retinal Disorders Market Forecast, 2009-2014Table 7.3 Regional Retinal Disorders Market Forecast, 2015-2024Table 9.1 Global Prevalence of AMD and DR Complications, 2008 and 2024List of FiguresFigure 4.1 Retinal Disorder Market in 2008Figure 4.2 World Retinal Disorder Market Forecast, 2009-2024Figure 4.3 Revenue Forecast by Retinal Disorder Type, 2009-2024Figure 4.4 Market Share Forecast by Retinal Disorder Type, 2009-2024Figure 4.5 AMD Market, 2008: Leading DrugsFigure 4.6 AMD Market, 2008: Leading ManufacturersFigure 4.7 Global AMD Market Forecast, 2009-2024Figure 4.8 Global DR Market Forecast, 2009-2024Figure 4.9 Lucentis Market Forecast (Main Forecast), 2009-2024Figure 4.10 Lucentis Market Forecast (Alternative Forecast), 2009-2024Figure 4.11 Visudyne Market Forecast, 2009-2014Figure 6.1 Forecasted World Population Aged 65 or Over, 2008-2024Figure 6.2 Population Forecasts in Leading AMD and DR Markets, 2008 & 2024Figure 6.3 Global, US and European AMD Prevalence, 2008Figure 6.4 Global, US and European AMD Prevalence, 2008 and 2024Figure 6.5 Global, US and European DME and PDR Prevalence, 2008Figure 6.6 Global, US and European Diabetes Prevalence, 2008 and 2024Figure 6.7 Global, US and European New Cases of DME, 2008 and 2024Figure 6.8 Global, US and European New Cases of PDR, 2008 and 2024Figure 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008Figure 7.2 Regional Retinal Disorders Market Forecast, 2009-2014Figure 7.3 Market Share Forecast by Regional Retinal Disorder Market, 2009-2024Figure 9.1 World Retinal Disorder Market Forecast, 2009-2024Figure 9.2 Lucentis Market Forecast, 2009-2024Companies ListedAlcon (Nestlé)Alimera SciencesAllerganAmerican Academy of Ophthalmology (AAO)American Society of Retinal Specialists (ASRS)AstraZenecaWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 6/10
    • Find Industry reports, Company profilesReportLinker and Market StatisticsBausch & LombBayerBioDiemBristol-Myers SquibbCentre for Molecular and Vascular Biology, KU LeuvenChugaiCoMentisDiabetic Retinopathy Clinical Research Network (DRCR)Eli LillyEmory UniversityESBATechEsteveEuropean Medicines Agency (EMEA)EyetechFood and Drug Administration (FDA)FoveaGene SignalGenentechGenVecGileadGlaxoSmithKline (GSK)iCoIsisJerini OphthalmicKAI PharmaceuticalsLpathLudwig-Maximilians-UniversitätMacuSightMerck & Co.Moorfields Eye HospitalNational Eye Institute (NEI)National Health Service (NHS)National Institute for Health and Clinical Excellence (NICE)National Institute for Health Research (NIHR)National Institutes of Health (NIH)NeurotechNeXstarNovartisOM PharmaceuticalsOphthotechOpkoOSI PharmaceuticalsOtheraOxford BioMedicaOxigenePfizerPotentiapSividaQLTQuarkWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 7/10
    • Find Industry reports, Company profilesReportLinker and Market StatisticsRegeneronRetinagenixRocheSantenSanwa Kagaku KenkyushoShireSirion TherapeuticsSirna TherapeuticsSirnaomicsSuzukenSymphony ViDATakedaTargeGenTargeted GeneticsThromboGenicsUniversity College LondonUniversity of FloridaUniversity of Kentucky College of MedicineVitreoretinal TechnologiesWyethWorld AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 8/10
    • Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 417.21 Quantity: _____ Department License--USD 4 834.42 Quantity: _____ Site License--USD 8 046.71 Quantity: _____ Corporate License--USD 11 265.95 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 9/10
    • Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 Page 10/10